# Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris

> **NCT01920477** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 35 (actual)

## Conditions studied

- Pemphigus Vulgaris

## Interventions

- **BIOLOGICAL:** Ofatumumab
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01920477
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-08-13
- **Primary completion:** 2016-04-13
- **Final completion:** 2018-01-11
- **Target enrollment:** 35 (ACTUAL)
- **Why stopped:** Novartis has acquired the rights to ofatumumab and terminated the OPV116910 and OPV117059 studies. This decision is not linked to any safety consideration.
- **Last updated:** 2019-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01920477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01920477, "Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01920477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*